시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 에스케타민 시장 보고서(2025년)
Esketamine Global Market Report 2025
상품코드 : 1750992
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,138,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,872,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,606,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

에스케타민 시장 규모는 향후 수년간 급성장이 예상될 예정입니다. 효과적인 치료법으로 에스케타민의 수용 확대에 기인하고 있습니다. 이 기간에 예상되는 주요 동향은 생명 공학 기업과 정신 건강 기관의 제휴, 건강 관리 응용 분야에서 로봇 공학의 사용, 맞춤형 의료 전략, 센서 기반 장치의 상승, 병용 요법의 가능성 등이 있습니다.

치료 저항성 우울증(TRD)의 유병률 증가가 향후 수년간 에스케타민 시장 확대를 이끌 것으로 예측됩니다. 우울증을 가리키는 치료 저항성 우울증 증가는 전통적인 항우울제의 효과가 제한적이며 우울증 에피소드의 장기화와 재발로 이어질 수있는 주요 원인입니다. 표적화된 속효 메커니즘을 제공함으로써 TRD에 대한 유망한 해결책을 제공하고 기존의 항우울제에 반응하지 않는 환자에게 구제를 제공합니다. 미국(NIMH)은 미국의 우울증 장애 환자의 약 30%가 표준 치료에 저항성을 보인다고 보고했습니다.

에스케타민이 치료 저항성 우울증에 대한 단일 요법으로 승인된 것은 TRD 치료의 획기적인 사건입니다. 2025년 1월 미국 제약회사 존슨 엔드 존슨은 미국 식품의약국(FDA)이 치료저항 우울증(TRD)의 성인환자에 대한 최초로 유일한 단제요법으로 SPRAVATO(에스케타민)를 승인했다고 발표했습니다. 이 승인은 SPRAVATO가 24시간 이내에 현저한 개선을 보였으며 우울증 증상을 신속하게 완화할 수 있음을 보여줍니다. SPRAVATO의 안전성 프로파일은 양호하지만, 잠재적인 부작용을 관리하기 위해 위험 평가 완화 전략(REMS)하에 투여됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Esketamine is a fast-acting anesthetic and antidepressant derived from ketamine, known for its NMDA receptor antagonist properties. It is primarily used to treat treatment-resistant depression and major depressive disorder with suicidal ideation, administered as a nasal spray under medical supervision.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main forms of esketamine include oral medications, injections, nasal sprays, and others. Oral medications consist of pills or tablets containing esketamine, which are taken orally to treat conditions such as depression. Its indications cover major depressive disorder, chronic pain, post-traumatic stress disorder, and anxiety disorders. The patient categories include adults, pediatrics, and geriatric patients. Esketamine is applied for general anesthesia and treatment-resistant depression, and it is distributed through various channels such as hospital pharmacies, online pharmacies, and retail pharmacies.

The esketamine market research report is one of a series of new reports from The Business Research Company that provides esketamine market statistics, including the esketamine industry global market size, regional shares, competitors with the esketamine market share, detailed esketamine market segments, market trends, and opportunities, and any further data you may need to thrive in the esketamine industry. This esketamine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The esketamine market size has grown rapidly in recent years. It will grow from$1.37 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth during the historic period can be attributed to a growing number of patients, the rising prevalence of mental health issues globally, improved awareness of the disease state, increased demand for innovative therapeutic options, and favorable regulatory approvals.

The esketamine market size is expected to see rapid growth in the next few years. It will grow to$2.31 billion in 2029 at a compound annual growth rate (CAGR) of 11.0%. The growth during the forecast period can be attributed to the rising prevalence of treatment-resistant depression, increased investment in research and development programs, demand for smart healthcare infrastructure, the growing adoption of telehealth services, and the increasing acceptance of esketamine as an effective treatment. Key trends expected during this period include partnerships between biotech companies and mental health organizations, the use of robotics in healthcare applications, personalized medicine strategies, the rise of sensor-based devices, and the potential for combination therapies.

The growing prevalence of treatment-resistant depression (TRD) is expected to drive the expansion of the esketamine market in the coming years. TRD refers to depression that does not improve despite trying at least two different antidepressant medications at appropriate doses for a sufficient duration. The rise in treatment-resistant depression is largely due to the limited effectiveness of conventional antidepressants, which leads to prolonged and recurring depressive episodes. Esketamine offers a promising solution for TRD by providing a rapid-acting mechanism that targets NMDA receptors, offering relief to patients who do not respond to traditional antidepressants. For example, in September 2023, the National Institute of Mental Health (NIMH) in the U.S. reported that approximately 30% of individuals with major depressive disorder in the U.S. are resistant to standard treatments. Consequently, the increasing incidence of treatment-resistant depression is fueling the growth of the esketamine market.

Esketamine's approval as a monotherapy for treatment-resistant depression marks a breakthrough in TRD treatment. Major companies in the esketamine market are focusing on developing advanced solutions such as monotherapy, which involves using a single drug to manage a condition, rather than combining multiple therapies. In January 2025, Johnson & Johnson, a U.S.-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression (TRD). Supported by clinical trial data, the approval showed that SPRAVATO could rapidly alleviate depressive symptoms, with significant improvements occurring within 24 hours. This breakthrough provides a vital option for the 30% of individuals who do not respond to traditional antidepressants, eliminating the need for additional oral medications. While SPRAVATO has a favorable safety profile, it is administered under a Risk Evaluation and Mitigation Strategy (REMS) to manage potential side effects. This milestone represents a major advancement in TRD treatment, offering renewed hope for better patient outcomes.

In April 2024, Celon Pharma S.A., a Poland-based pharmaceutical company, partnered with Tang Capital Management LLC to create Novohale Therapeutics, LLC. This collaboration is focused on advancing the development of Falkieri, an esketamine dry powder inhalation product, into global Phase 3 clinical trials for bipolar depression. Tang Capital Management LLC, a U.S.-based company specializing in life sciences and biotechnology, is working with Celon Pharma to bring this innovative treatment to market.

Major players in the esketamine market are Cigna Corporation, Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Horizon Therapeutics plc, Hikma Pharmaceuticals plc, Alkem Laboratories Limited, Cerecor Inc., Celon Pharma S.A., Nortec Quimica S.A., XWPharma Ltd., Seqens Group, SynZeal Research Pvt. Ltd., Arevipharma GmbH, Sage Therapeutics Inc., Supriya Lifescience Ltd., Clexio Biosciences Ltd., Maithri Drugs Pvt. Ltd., and VistaGen Therapeutics Inc.

North America was the largest region in the esketamine market in 2024. The regions covered in esketamine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the esketamine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The esketamine market consists of sales of products including spravato, and esketamine injectable formulations. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Esketamine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on esketamine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for esketamine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The esketamine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Esketamine Market Characteristics

3. Esketamine Market Trends And Strategies

4. Esketamine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Esketamine Growth Analysis And Strategic Analysis Framework

6. Esketamine Market Segmentation

7. Esketamine Market Regional And Country Analysis

8. Asia-Pacific Esketamine Market

9. China Esketamine Market

10. India Esketamine Market

11. Japan Esketamine Market

12. Australia Esketamine Market

13. Indonesia Esketamine Market

14. South Korea Esketamine Market

15. Western Europe Esketamine Market

16. UK Esketamine Market

17. Germany Esketamine Market

18. France Esketamine Market

19. Italy Esketamine Market

20. Spain Esketamine Market

21. Eastern Europe Esketamine Market

22. Russia Esketamine Market

23. North America Esketamine Market

24. USA Esketamine Market

25. Canada Esketamine Market

26. South America Esketamine Market

27. Brazil Esketamine Market

28. Middle East Esketamine Market

29. Africa Esketamine Market

30. Esketamine Market Competitive Landscape And Company Profiles

31. Esketamine Market Other Major And Innovative Companies

32. Global Esketamine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Esketamine Market

34. Recent Developments In The Esketamine Market

35. Esketamine Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기